Medicine
Naropin 40 mg/20 mL injection
Naropin 40 mg/20 mL injection is a prescription medicine containing Ropivacaine for epidural, infiltration use, marketed by Fresenius Kabi, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Solutions should be stored at 20ºC to 25°C (68ºF to 77°F), excursions…
Key facts
- Active ingredient (INN)
- Ropivacaine
- Brand
- Naropin
- Strength
- 40 mg/20 mL
- Dosage form
- Injection
- Route
- Epidural, infiltration
- Packs
- 5 ampules of 20 mL, 25 vials of 20 mL
- Marketing authorisation holder
- Fresenius Kabi
- Manufacturer
- Fresenius Kabi
- Origin register
- US FDA, United States
- Storage
- Solutions should be stored at 20ºC to 25°C (68ºF to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 24 September 1996
- Identifiers
- RxCUI 1734203, 1734204, 1734207 +7DailyMed set ID dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7, 23d2d448-a744-4877-9f2d-7e57c198da89NDC 63323-285Application NDA020533
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 5 ampule in 1 box / 20 mL in 1 ampule | 63323-285-20 | Fresenius Kabi | 31 May 2011 |
| 25 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 63323-285-23 | Fresenius Kabi | 31 May 2011 |
| 25 vial, single-use in 1 carton / 20 mL in 1 vial, single-use | 63323-285-28 | Fresenius Kabi | 4 August 2009 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 24 September 1996 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Ropivacaine 40 mg/20 mL injection.
Other strengths and forms of Ropivacaine
Clinical summary
Ropivacaine is an amide local anesthetic indicated for the production of local or regional anesthesia for surgery and for acute pain management. It is available as injection for epidural, infiltration and perineural use. MedsAcross supplies Ropivacaine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about RopivacaineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Naropin prescribing information (Fresenius Kabi) · U.S. National Library of Medicine, DailyMed
Need Naropin 40 mg/20 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.